|Day Low/High||46.10 / 48.82|
|52 Wk Low/High||30.15 / 64.94|
China trade issue is no longer dominating the action.
There is no respite today from the poor price action in individual stocks.
I still believe it will be a big year for buyouts across the biotech industry.
If the market wanted an excuse to sell off it had it.
Apple in particular is helping the bullish cause.
If there is any good news on trade the potential for more market upside is strong.
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
You don't have to 'believe' in technical analysis to use it to set your exit and entry points.
There is no question that we are becoming extended and ripe for some profit taking.
Overall it is still a positive day but the action is sloppy.
No matter what happens with Iran, it is not going to be a major market positive.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
It is important to note that watching for a reversal is much different than being short.
The bears are likely to be increasingly bold if there's a failed bounce.
It would be a longer-term positive if the overbought conditions are alleviated.
You have to wonder how much longer we can run without a pullback of at least 2%.
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
There is still a very strong appetite for individual stocks with momentum.
I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.
But you need to be selective and have discipline.
U.S. stocks move higher after early slip, as investors digest Apple's latest results.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
The major indices barely budged intraday this week, as we had the narrowest trading range ever.